Gilead Is Wise to Leave Remdesivir Money on the Table

Gilead could have commanded a higher price for its Covid-19 treatment, but investors should be happy to see restraint.

Gilead Is Wise to Leave Remdesivir Money on the Table
Gilead could have commanded a higher price for its Covid-19 treatment, but investors should be happy to see restraint.